Oragenics, Inc.

Latest News

Oragenics to Participate in the 2022 BioFlorida Annual Conference

Innovative Biopharmaceuticals for Infectious Diseases

Oragenics is focused on developing NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 caused by the SARS-CoV-2 virus and its variants.

Learn More About Oragenics

Fighting Global Bacterial Antibiotic Resistance

Oragenics is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.

Learn More About Lantibiotics

Sign up for email updates

Be the first to receive breaking news

Sign Up

Investors Presentation

View our latest Corporate Presentation

View presentation ยป
Oragenics Pesentation
NYSE American OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Last Updated: